Literature DB >> 15744585

Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Jürgen Sonnemann1, Jennifer Gänge, K Saravana Kumar, Cornelia Müller, Peter Bader, James F Beck.   

Abstract

Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and histone deacetylase inhibitors (HDIs) show promise for the treatment of cancer. However, in a number of reports they have been proven ineffective to induce cell death when applied as single agents. In this study, we show that A549 lung carcinoma cells and PC-3 prostate carcinoma cells underwent substantial apoptosis when coexposed to TRAIL and either suberoylanilide hydroxamic acid, sodium butyrate or trichostatin A. HDIs and TRAIL synergized in activation of capase-3, induction of internucleosomal DNA fragmentation and promoting mitochondrial damage. Significantly, cotreatment with minimally toxic doses of HDIs and TRAIL resulted in a marked apoptotic response in both cell lines. These data provide a rationale for a more in-depth exploration into the potential of combining TRAIL and HDIs as a valuable anticancer strategy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744585     DOI: 10.1007/s10637-005-5854-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  45 in total

1.  Deacetylation of p53 modulates its effect on cell growth and apoptosis.

Authors:  J Luo; F Su; D Chen; A Shiloh; W Gu
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate.

Authors:  B Bonnotte; N Favre; S Reveneau; O Micheau; N Droin; C Garrido; A Fontana; B Chauffert; E Solary; F Martin
Journal:  Cell Death Differ       Date:  1998-06       Impact factor: 15.828

3.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

Authors:  R L Piekarz; R Robey; V Sandor; S Bakke; W H Wilson; L Dahmoush; D M Kingma; M L Turner; R Altemus; S E Bates
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

4.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

Review 5.  Mechanisms of caspase activation and inhibition during apoptosis.

Authors:  Yigong Shi
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

6.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Authors:  Wm Kevin Kelly; Victoria M Richon; Owen O'Connor; Tracy Curley; Barbara MacGregor-Curtelli; William Tong; Mark Klang; Lawrence Schwartz; Stacie Richardson; Eddie Rosa; Marija Drobnjak; Carlos Cordon-Cordo; Judy H Chiao; Richard Rifkind; Paul A Marks; Howard Scher
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.

Authors:  Fei Guo; Celia Sigua; Jianguo Tao; Purva Bali; Prince George; Yunqing Li; Sylvie Wittmann; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

8.  Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells.

Authors:  Frans Van Valen; Simone Fulda; Karl-Ludwig Schäfer; Borna Truckenbrod; Marc Hotfilder; Christopher Poremba; Klaus-Michael Debatin; Winfried Winkelmann
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

9.  Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.

Authors:  Jiri Neuzil; Emma Swettenham; Nina Gellert
Journal:  Biochem Biophys Res Commun       Date:  2004-01-30       Impact factor: 3.575

10.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

Authors:  Roberto R Rosato; Jorge A Almenara; Yun Dai; Steven Grant
Journal:  Mol Cancer Ther       Date:  2003-12       Impact factor: 6.261

View more
  12 in total

1.  Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.

Authors:  Terry W Moody; Tomoo Nakagawa; Yang Kang; Sonia Jakowlew; Daniel Chan; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.

Authors:  Rosario Yerbes; Abelardo López-Rivas
Journal:  Invest New Drugs       Date:  2010-11-25       Impact factor: 3.850

3.  Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells.

Authors:  Matthias Felber; Jürgen Sonnemann; James F Beck
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

Review 4.  Vorinostat in solid and hematologic malignancies.

Authors:  David Siegel; Mohamad Hussein; Chandra Belani; Francisco Robert; Evanthia Galanis; Victoria M Richon; José Garcia-Vargas; Cesar Sanz-Rodriguez; Syed Rizvi
Journal:  J Hematol Oncol       Date:  2009-07-27       Impact factor: 17.388

5.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Authors:  Jürgen Sonnemann; Linn Dreyer; Maite Hartwig; Chithra D Palani; Le Thi Thu Hong; Ulrike Klier; Barbara Bröker; Uwe Völker; James F Beck
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

6.  Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5.

Authors:  Young-Hwa Jung; Jeonghoon Heo; Yong J Lee; Taeg Kyu Kwon; Young-Ho Kim
Journal:  Life Sci       Date:  2010-01-21       Impact factor: 5.037

7.  Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

Authors:  Annick Mühlethaler-Mottet; Marjorie Flahaut; Katia Balmas Bourloud; Katya Auderset; Roland Meier; Jean-Marc Joseph; Nicole Gross
Journal:  BMC Cancer       Date:  2006-08-24       Impact factor: 4.430

Review 8.  Targeting histone deacetylases for the treatment of disease.

Authors:  M W Lawless; S Norris; K J O'Byrne; S G Gray
Journal:  J Cell Mol Med       Date:  2008-11-03       Impact factor: 5.310

9.  The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.

Authors:  Min Ho Han; Cheol Park; Taek Kyu Kwon; Gi-Young Kim; Wun-Jae Kim; Sang Hoon Hong; Young Hyun Yoo; Yung Hyun Choi
Journal:  Biomol Ther (Seoul)       Date:  2015-01-01       Impact factor: 4.634

Review 10.  Mesenchymal stem cells as vectors for lung cancer therapy.

Authors:  Krishna K Kolluri; Geoff J Laurent; Sam M Janes
Journal:  Respiration       Date:  2013-05-23       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.